Trials / Completed
CompletedNCT00150813
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- UCB Pharma SA · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam | Pharmaceutical form: oral tablets Route of administration: Oral use |
Timeline
- Start date
- 2005-08-10
- Primary completion
- 2007-05-29
- Completion
- 2007-05-29
- First posted
- 2005-09-08
- Last updated
- 2018-11-21
- Results posted
- 2018-10-01
Locations
21 sites across 4 countries: Czechia, Hungary, Poland, Sweden
Source: ClinicalTrials.gov record NCT00150813. Inclusion in this directory is not an endorsement.